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Abstract
Atherosclerosis is nowadays generally accepted as an inﬂammatory disease but the mechanism of its origin and development
have not yet been fully clariﬁed. The present review focuses on the role of the local immune system as one of the key players in
the pathogenesis of the complex process. Its part represented by vascular-associated lymphoid tissue (VALT) within the
arterial wall participates directly in the vascular wall’s homeostatis. Its inordinate activation during ontogenic development of
an individual, this formerly defensive and physiologic mechanism transform into a pathological process resulting in an
impairing inﬂammation. Hsp60, CRP and oxidized or otherwise modiﬁed LDL are serious candidates for triggering these
pathological changes. The principal role is played by anti-Hsp60 antibodies and by shear stress originating on the surface of
endothelium due to blood ﬂow. The experimental and clinical data supporting this immunological hypothesis of
atherosclerosis are discussed.
Introduction
Despite the fact that atherosclerosis has been subject
to intensive research, its mechanisms of origin and
development (atherogenesis) have not yet been fully
clariﬁed. Many cells and mediators that are typical
representatives of inﬂammatory reactions participate
also in atherosclerosis. Therefore, it is justiﬁed to
assume that atherogenesis represents an inﬂammatory
process (Ross 1999), the regulation of which is
affected by many intervening risks. According to the
American Heart Association, 268 such factors are
currently known. This indicates that atherosclerosis is
not a simple reaction but a complex process
developing in course of many years. On the other
hand, a serious doubt can be expressed as to whether
all of these factors represent real risks of atherogenesis
or whether many of them are rather triggering or
initiating factors that steer latent processes and to a
certain extent also physiologic processes into known
pathological clinical signs, as, e.g. ischemic heart
disease, myocardium infarction or a cerebrovascular
stroke. This can be supported by the fact that only
50% of patients with the disease actually manifest
hyperlipidemia, the popular major secondary risk
factor targeted for intervention world/wide (EURO-
ASPIRE 1997). Furthermore, the prevalence of
traditional risk factors such as smoking, hypertension
and diabetes is only slightly higher in patients with
documented cardiac or peripheral vascular disease
compared to similarly elderly patients without disease
(Greenland et al. 2003). On the other hand, a
signiﬁcant percentage of aged people who have never
developed clinical cardiovascular symptoms and died
due to other reasons have developed progressive
atherosclerosis of major and medium arteries.
It seems that, so far the only indubitably documen-
ted process taking place in coincidence with the origin
and development of atherosclerosis is the remodelling
of arterial vascular wall and local chronic inﬂam-
mation. It is the immune system that participates in
remodelling and all forms of inﬂammation. The
inﬂammation is a phylogenetically and ontogenetically
the oldest mechanism of innate immunity, the primary
function of which is a protective reaction in response
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reaction be not sufﬁciently regulated, it may develop
into impairing inﬂammation. In both protective and
impairing types of inﬂammation, basic cells of the
immune system are engaged, as neutrophils, macro-
phages or T lymphocytes, including endothelial and
vascular smooth muscle cells (VSMC) in case of
inﬂammation of vascular wall. These processes are
affected by both pro-inﬂammatory and anti-inﬂam-
matory mediators released especially by participating
cells, as, e.g. cytokines, prostanoids, adhesive and
chemotactic molecules and C-reactive protein (CRP)
(Langheinrich and Bohle 2005, Mullenix et al. 2005).
Should the inﬂammation be a natural response to
the impairment of tissue, the knowledge of the
mechanism, by which the vascular wall is impaired
and subsequently afﬂicted by inﬂammation and
atherosclerosis, is crucial. Out of several theories,
trying to explain this mechanism, it is the auto-
immunity theory that is of remarkable signiﬁcance
(Wick et al. 2001).
Atherosclerosis as an inordinate activation of the
immune system
Autoimmune diseases occur due to inordinate
activation of the immune system and insufﬁciently
regulated immune response. The reason resides in
strong or long-term antigenic stimuli turning the
original physiological and regulatory functions of
autoimmune responses into auto-aggressive
reactions.
The viability of the idea that atherosclerosis
originates and develops on the basis of pathological
autoimmune mechanism is indicated by two facts: (1)
The process of atherosclerosis meets all of the
determinant criteria worked out by Witebsky and
Rose for including a disease unit into the category of
autoimmunediseases.(2)Insomeclassicautoimmune
diseases as systemic lupus erythematosus (SLE), anti-
phospholipid syndrome (APS) or rheumatoid arthritis
(RA) an accelerated progression of atherosclerosis is
observed. In vasculitis, the vessel originally afﬂicted by
inﬂammation tends to become liable to succumbing to
atherosclerosis (S ˇtvrtinova ´ et al. 2001).
Criteria indicating that auto-aggressive reactions
participate in the pathogenesis of atherosclerosis are as
follows:
1. The presence of speciﬁc auto-antigens. In athero-
sclerosis, it is the group of heat shock proteins
Hsp60/65, oxidized low-density lipoprotein
(oxLDL) and b2-glycoprotein-1 (b2GP-1).
2. Active immunization in experimental animals. The
immunization with Hsp60, oxLDL and b2GP-1
induces the production of speciﬁc antibodies.
3. The evidence of the pathogenetic role of autoanti-
bodies. Autoantibodies against Hsp60 and b2GP-1
enhance the progression of atherosclerosis whereas
autoantibodies against oxLDL have a protective
function.
4. Passive transfer of disease by means of T
lymphocytes. It has been proved that in mice the
administration of speciﬁc anti-Hsp60 and anti-
b2GP-1 T lymphocytes induces the origin and
development of atherosclerosis.
5. Immunomodulation therapy decreases the occur-
rence and intensity of experimental atherosclerosis
in mice.
Among the above autoantigens, most signiﬁcant are
Hsp60 heat shock proteins being released from
various cells of macroorganism during stress, or
descending from some of bacterial species (chlamy-
dia) and viruses. Other bacteria (mycobacteria)
release an Hsp65 protein, which is similar to the
former. The molecules of Hsp60 and Hsp65
descending from various sources greatly relate in
their primary structure and that is why antibodies
formed against Hsp60 of chlamydia react also with
Hsp60 released from stressed cells of macroorganism.
This reaction brings about the formation of immune
complexes that activate the complement and trigger
the inﬂammatory reaction (Wick et al. 2001). Patients
with atherosclerosis yield increased levels of autoanti-
bodies and increased counts of T lymphocytes aimed
at heat shock proteins, especially at Hsp60, the fact of
which might be of value in prognosis and diagnosis
(Mandal et al. 2004).
It was also shown that immunization of mice with
Hsp60 and with b2-GPI served to enhance the
progression of atherosclerosis and led to an increase
in the inﬁltration of T lymphocytes in the suben-
dothelial regions of the early plaques (Shoenfeld et al.
2000).
In addition to their key role in the origin of foam
cells, oxidized LDLs have a direct cytotoxic effect on
endothelial cells as well as a strong immunogenic
impact. Due to the latter fact, autoantibodies of
natural character are formed against them. Anti-
oxLDL antibodies have a protective effect on the
formation of foam cells, because they slow down
the interaction of oxLDL with scavenger receptors on
the surface of monocytes, macrophages and smooth
muscle cells. On the other hand, their immune
complexes on the surface of endothelial cells stimulate
the inﬂammatory reaction (Gordon et al. 2001,
Frostegard 2002).
The incidence of cardiovascular diseases is 50-fold
higher in women suffering from SLE than in those
not suffering from the latter disease (Manzi et al.
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sclerosis and their subsequent manifestations have
been found in people suffering from antiphospholipid
syndrome (George and Shoenfeld 1997, Gordon et al.
2001).
A thorough investigation carried out in recent years
has shown that in addition to autoimmune mechan-
isms represented by autoantibodies and speciﬁc T
lymphocytes, there are also other parts of the immune
system that participate in atherosclerosis.
Immunological hypothesis of atherosclerosis
The current immunologic hypothesis of the origin and
development of atherosclerosis is based on the
assumption that its core resides in insufﬁciently
regulated local immune response.
It mainly implies from immunohistologic obser-
vations of veryearly clinically latent arterial changes.It
has been revealed that the primary cells appearing in
arterial intima in sites predetermined for athero-
sclerotic lesions are not the foam cells, but the
lymphoid cells followed by macrophages and smooth
muscle cells (Xu et al. 1990). Out of lymphoid cells,
especially the helper (CD4
þ) T lymphocytes are
signiﬁcantly more abundant than cytotoxic (CD8
þ)T
lymphocytes. Out of individual subpopulations of TH
lymphocytes it is the subpopulation of TH1 lympho-
cytes that prevails. As to their phenotype, they are
focused on the secretion of pro-inﬂammatory cyto-
kines (TNF, IFN-g and IL-2). Such an inﬁltration of
arterial intima with mononuclear cells occurs as early
as in one-year-old children. Up to 8–10 years of age
neither foam cells nor extracellular LDL deposits are
present (Millonig et al. 2002). In addition to T
lymphocytes, macrophages and smooth muscle cells,
normal arterial intima contains also scattered mast
cells and a signiﬁcant amount of immature forms of
dendritic cells (Bobryshev and Lord 1999, Bobryshev
2000). They are present not only in intima, but also in
adventitia. They mature later during the development
of atherosclerosis.
The stimuli enhancing atherosclerosis including
oxLDL increase the adhesion of dendritic cells to the
endothelium and their migration into the intima
(Alderman et al. 2002). After endothelial transmi-
gration they settle in sites where arteries are exposed
to the main hemodynamic stress. In these sites,
they can participate in the development of
atherosclerosis.
Inﬁltrations of mononuclear cells in intima,
primarily in sites predetermining the origin of
atherosclerotic lesions form vascular-associated lym-
phoid tissue (VALT) (Waltner-Romen et al. 1998).
VALT can be considered to be an analogue of MALT,
i.e. mucose-associated lymphoid tissue. It is true,
however, that the local accumulation of cells in MALT
is signiﬁcantly more extensive than in VALT. MALT
represents the local immune system of mucose. Its
primary task is to carry out local immune responses. It
is therefore, possible to assume that VALT has also a
similar function. The latter statement is supported by
the fact that VALT is present in all people regardless of
age. In children up to 10 years of age, the cells of
VALT are mostly in inactive state and can be
considered to be natural structures. However, VALT
in young Americans with no symptoms of cardio-
vascular diseases already at the age of 15–34 years
contains cells yielding some signs of proinﬂammatory
activities (Millonig et al. 2002).
The cells inﬁltrating the intima under physiological
conditions as well as in progressive atherosclerosis are
part of mechanisms of natural and acquired immunity.
The role of innate immunity in atherosclerosis
Multi-cellular organisms including humans have deve-
loped and currently exist amidst masses of microorgan-
isms. Therefore, on their own cells they had to develop
biosensorsenablingthemtoberecognizedfromthoseof
microbes. This recognising system not only initiates the
liquidationofpathogenicmicrobesthathavepenetrated
into the organism, but also prevents their genetic
material from combining with that of the cells of
macroorganism. This system participates in innate
immunity mechanisms. It is based on highly conserved
pattern-recognition receptors (PRRs). They occur
especially on cells that come into contact with external
surroundings and pathogens as well as on VALT cells.
PRRs are composed of two basic groups:
1. Receptors facilitating phagocytosis, i.e. opsonin
receptors, as, e.g. receptors of immunoglobulin Fc-
domains (especially FcgR), C3b fragment of
complement (CR1, CR3) and lectin receptors.
2. Toll-like receptors: 11 of them are known and
referred to as TLR1–TLR11. TLRs recognize
pathogen-associated molecular patterns (PAMPs).
This mechanism enables the several dozens of
receptors to recognize molecular patterns of pathogens
occurring in thousands of microorganisms’ species
withinourenvironment.Thisisenabled bythe fact that
aparticularpathogenpatternoccursinseveralspeciesof
microorganisms. Lipopolysaccharide (LPS) occurring
onthesurfaceofmanygram-negativebacteriacanserve
asanexampleofpathogenpattern,aswellaslipoteichoic
acid,whichisacharacteristicmolecularpatternofgram-
positive bacteria.PRRs, however, donot recognize only
molecular patterns occurring on the surface of
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cules (especially proteins) descending from the cells
belonging to the macroorganism. These originate in
various stress situations, as oxidation stress, presence of
heavy metals and analogues of amino acids, heat,
ionising radiation, etc. This means that they are the
actual sensors of risks endangering the homeostasis of
organism (Medzhitov 2001, Vink et al. 2004).
When PPR on the surface of T lymphocytes,
macrophages, endothelial or smooth muscle cells in
the vascular wall recognizes a particular PAMP, the
protective inﬂammation is initiated. In case that the
presence of such PAMP persists, the inﬂammation
becomes chronic and incurs damage. The latter facts
imply that the initiating stimuli can be endogenous as
well as exogenous factors, while their number can be
relatively large.
One of them is oxLDL, which contains a denatured
protein representing the pathogenic pattern. There-
fore, it is a speciﬁc ligand for PRRs (especially for
CD14/TLR4 and CD36 receptors) on cells occurring
in VALT. Already in small concentrations these cells
stimulate the protective inﬂammatory reaction. If the
presence of oxLDL persists, the protective inﬂam-
mation turns into damage-incurring reaction. This
can be one of early initiating factors of atherogenesis.
At an increased concentration of oxLDL, the latter by
means of scavenging receptors penetrates into mono-
cytes, macrophages, smooth muscle and dendritic
cells that turn into foam cells typical for the
progressive stage of atherosclerosis.
The earliest effects of oxLDL include also the
stimulation of expression of VCAM-1, vascular cell-
adhesion molecule on endothelial cells of arteries.
VCAM-1 is the crucial adhesion and chemotactic
moleculeformonocytesandTlymphocytes.Inaddition
to the latter, oxLDL have a toxic effect on endothelial
cells and a mitogenic impact on macrophages and
smooth muscle cells (Wick et al. 2004). These proper-
ties allow oxLDL to be evaluated as one of the ﬁrst
initiating factors of atherogenesis as it stimulates not
onlythepro-atherogenicchangeofendothelialcells,but
also the migration of monocytes and macrophages into
intima and proliferation of smooth muscle cells.
In addition of oxLDL, PRRs recognize also other
pathogenic patterns, namely those originating in
injured cells of macroorganism. From the aspect of
atherogenesis, the most important are the heat shock
proteins with their relative molecular weight of 60
000—Hsp60 (Mandal et al. 2004). The family of
Hsp60 contains highly conserved proteins, the amino
acid composition of which is very similar to those of
bacteria as well as of mammals including man. This
enables various immunologic cross reactions to take
place among autologous and microbial Hsp60. Hsp60
produce cells in result of the impact of various
stressors. For example, human endothelial cells
express Hsp60 in result of mechanical or heat stress,
oxygen radicals, toxins, heavy metals, infectious
agents, inﬂammatory cytokines, etc. (Xu and Wick
1996). Hsp60 are typical mitochondrial proteins and
under the condition of stress they migrate to the
surface of cells. That is why their appearance on the
cellular surface is the manifestation of danger and
represents a pathological pattern recognized by TLR-
4 and -6 (Chen et al. 1999, Habich et al. 2002).
Atherogenesis also involves several components of
humoral innate immunity as, e.g. natural antibodies,
complement, CRP, mataloproteinases and their
inhibitors (Wick et al. 2004).
The task of acquired immunity in atherogenesis
Mechanisms of acquired immunity participate in
atherogenesis by means of antibodies and T lympho-
cytes. Antibodies against autologous or exogenous
antigens localized within the arterial wall form
immune complexes with the latter. These complexes
activate the complement, which injures the surround-
ing cells and triggers the inﬂammatory reaction. At the
same time endothelial cells are activated. They express
adhesion molecules to an increased extent, by means
of which monocytes and other blood cells participat-
ing in the atherosclerotic process can adhere to the
endothelium.
T lymphocytes occurring in human atherosclerotic
plaques are of polyclonal origin. This means that at
the time when they get into the plaques they are either
already in an activated state or they become activated
in the plaque by means of several antigens or cytokines
(Stemme et al. 1991). The plaques contain more TH1
lymphocytes producing typical pro-inﬂammatory
cytokines (TNF-a, IFN-g, IL-2) than TH2-lympho-
cytes releasing anti-inﬂammatory IL-4, IL-5 and IL-
10. Pro-inﬂammatory cytokines activate the local
macrophages and inhibit the proliferation of smooth
muscle cells of vessels. Due to the latter facts, the risk
of plaque instability and rupture increases. As
opposed to the latter, the anti-inﬂammatory cytokine
TGF-b secreted by macrophages, TH3-lymphocytes
and smooth muscle cells have a pro-ﬁbrotic effect and
contribute to the stability of plaques (Mallat et al.
2001). The role of lymphocytes can be indicated also
by the fact that a loss of spleen being an important
secondary lymphatic organ leads to a severe manifes-
tation of atherosclerosis (Witztum 2002).
Atherogenesis can involve also immune reactions in
response to some infectious agents as, e.g. Chlamydia
pneumoniae and some viruses. At the same time, there
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of infectious agents that have infested a particular
individual and the stage of atherosclerosis in his/her
arteries (Epstein et al. 2000). This applies especially in
case of infectious agents that release high concen-
trations of Hsp60/65. This can be proved by the fact
that the level of autoantibodies and T lymphocytes
focused against Hsp60/65 signiﬁcantly increases in
people with severe atherosclerosis (Mandal et al.
2004).
Inﬂammatory mediators and atherosclerosis
Chronic inﬂammatory processes become evident by
increased blood levels of several markers, including
sedimentationoferythrocytes,leukocyteandneutrophil
counts, CRP level, a1-antitrypsine, ceruloplasmin,
soluble adhesion molecules sICAM-1 (sCD54),
sVCAM-1 (sCD106) and soluble E-selectin
(sCD62E), sHsp60 and endotoxin (LPS). A signiﬁcant
coincidencewithatherosclerosishasbeenfoundincases
of CRP, sHsp60, sVCAM-1, sCD62E, CD40-CD40L
(CD154) interaction and LPS (Lind 2003).
However, some other mediators can participate in
atherosclerosis. Some of them can have a stimulatory
effect on its process whereas others inhibit them
(Greaves and Channon 2002). The pro-atherogenic
effect is induced by IFN-g,I L - 1 b, IL-8 (chemokine
CXCL8), IL-12, IL-18, MCP-1, (chemokine CCL2)
and interaction CD40–CD154. The anti-atherogenic
effect has been observed in coincidence with IL-4, IL-
10, TGF-b and PPR-g. In addition to typical
cytokines, a signiﬁcant pro-atherogenic effect has
been proved in coincidence with some chemokines. In
this sense, the most important is the monocyte
chemoattractant protein MCP-1. The chemotactic
activity on monocytes has been proved also in other
chemokines of group CXCL, as, e.g. IL-8. Other
chemokines occur in atherosclerotic plaques:
CXCL10, CX3C (fractalkin), CCL11 (eotaxin),
CCL17 and CCL22. Unfortunately, their precise
roles in atherogenesis have not been clariﬁed yet.
C-reactive protein
The CRP is one of the earliest diagnostic inﬂamma-
tory markers. Its concentration in blood serum
increases several 100-fold in the case of inﬂammation
when compared with normal levels. The limit of its
detection by common methods is 5–10mg/l, and
these values used to be considered as normal.
C u r r e n t l y ,ah i g h l ys e n s i t i v em e t h o dh a sb e e n
introduced decreasing this limit to 0.1mg/l. By
means of the latter, it is possible to assess high-
sensitivity CRP (hsCRP). This fact has enabled the
hsCRP to serve as the risk marker of atherosclerosis.
This possibility is supported by epidemiologic studies
(Ridger et al. 2002, Wang et al. 2002) showing that
hsCRP values in people with cardiovascular diseases
increase and signify the risk of coronary diseases,
myocardium infarction, cerebrovascular stroke and
cardiovascular death.
Currently, the values of 0.1–0.7mg/l (yielded by
20% of population) are considered as normal; high
values are those over 3.8mg/l (20% of population).
Individuals with values below 1mg/l encounter a low
risk of cardiovascular diseases; those with values of
1–3mg/l are exposed to a moderate risk, whereas the
valuesof3–10mg/lrepresentahighrisk(Pearsonetal.
2003, Libby and Ridger 2004).
However, CRP is a non-speciﬁc marker of
inﬂammation and its concentration in chronic diseases
as, e.g. in rheumatoid arthritis, infections, trauma or
surgical interventions can signiﬁcantly exceed the
value of 3.8mg/l. CRP values are increased in aged
women, after hormonal replacement therapy as well as
in diabetic and obese patients. These situations must
be regarded when assessing the prognosis.
CRP is not only a prognostic marker of athero-
sclerosis, but it also participates in its pathogenesis. It
can directly injure the vascular endothelium, induce
atherosclerotic lesions including the mobilisation of
macrophages and the formation of foam cells. There-
fore, it is an important therapeutic target in primary
prevention and therapy of diseases caused by
atherosclerosis (Labarrere and Zaloga 2004).
Soluble Hsp60
The sHsp60 increases signiﬁcantly in patients with
atherosclerosis located incarotid vessels and correlates
with the thickness of arterial intima and media (Xu
et al. 2000). It has been found out that the serum level
of sHsp60 directly correlates with the titre of
antibodies against Hsp60, LPS and chlamydia. In
some patients, sHsp60 concentrations exceeded
1mg/l. Increased sHsp60 concentrations have been
found also in patients with hypertension and initial
atherosclerosis (Pockley et al. 2000). The origin of
sHsp60 is not known. Principally, it can be released
from cells of human body after various physical,
chemical, biological and psychological stressors or it
can descend from infectious agents or released by
inﬂammatory cells in effect of inﬂammatory cytokines.
In addition to the latter, sHsp60 can descend from
microparticles released from apoptotic and mechani-
cally injured cells (Mallat and Tedgui 2001).
Defects in regulation of local immune responses 229CD40/CD40L interaction
The CD40 is a receptor, whose ligand is CD40L
(CD154). It occurs on the surface of many cells
including endothelial and smooth muscle cells,
T lymphocytes, macrophages and platelets as well as
on those occurring in atherosclerotic plaques. CD40 is
on the surface of activated T lymphocytes or in a
soluble (sCD40L) form. The interaction between
CD40 and CD40L induces a number of biochemical
reactions and subsequent biologic manifestations of
cells carrying CD40 molecules. It is applied also in
atherogenesis, namely by increasing the expressions of
intracellular metaloproteinases, pro-coagulation tis-
sue factor, chemokines and inﬂammatory cytokines
(Schoenbeck and Libby 2001a). When compared with
membranous CD40, the soluble CD40 lacks a part of
molecule. Despite the latter fact, biological activities
of both are equal. The concentration of sCD40L in
patients with cardiovascular diseases is increased and
therefore it can be considered as a risk factor of
prognostic value (Schoenbeck and Libby 2001b).
Endothelial cells as a part of the immune system
In addition to basic functions in the regulation of
cardiovascular system, vascular endothelial cells are
also an important component of the immune system.
In many ways, they are similar to macrophages as to
their properties and their key role in initiating and
developing the protective as well as impairing
inﬂammatory responses. Endothelium can be con-
sidered as a particular transmission facility enabling
bi-directional exchange of information between the
cardiovascular and immune systems (S ˇtvrtinova ´ et al.
1998). Mechanical or inﬂammatory impairments of
endothelial integrity serve as initiating or triggering
factors of atherosclerosis. They involve both hemo-
dynamical and immune mechanisms. The impairment
of endothelial monolayer results in dysfunction of
endothelium or even apoptosis of endothelial cells.
Both not only initiate these events, but also develop
the process of atherosclerosis. Apoptosis results in the
formation of apoptotic microparticles and in the need
to replace the cells released from the endothelial layer.
The mechanical impairment or apoptotic destruc-
tion results in the formation of endothelial micro-
particles. The latter represent various fragments of
endothelial cells. They represent about 30% of cellular
microparticles that are present in circulation of
healthy people. The rest of them are microparticles
of platelets and leukocytes. Their amount increases in
coincidence with various diseases including coronary
syndromes (Diamant et al. 2004). These particles link
with various inﬂammatory mediators, thus enabling
their impact also beyond the site of their origin. They
can settle in sites of injured endothelium, the fact of
which can be proved by evidence that endothelial
microparticles are the main components of athero-
sclerotic plaques.
Apoptosis of individual cells in endothelial mono-
layer takes place not only in result of impairment, but
also in result of their normal biologic turnover, which
is substantially higher than previously considered. In
both cases, the missing cells are to be replaced. Such
regeneration of endothelium can be carried out by
means of circulating endothelial cells or by angiogen-
esis. It seems that the replacement by means of
circulating endothelial cells is faster. Their origin is
not precisely known. They can descend from bone
marrow (progenitor endothelial cells), from tissue
stem cells or from transformed blood monocytes
(Dimmeler and Zeiher 2004). It is assumed that they
play a key role in maintaining the integrity of
endothelium and thus also in the prevention of
atherosclerosis and thrombus complications. This is
suggested also due to the fact that in patients with
coronary diseases, the amount of circulating progeni-
tor endothelial cells is signiﬁcantly decreased (Vasa
et al. 2001a). The reason of this decrease can reside in
the depletion of stem and progenitor cells stored in
bone marrow, their decreased mobilisation or
decreased lifetime (biological half-time period).
Should the insufﬁcient function of circulating
progenitor endothelial cells really apply in the
development of atherosclerosis and coronary disease,
the pharmacologically induced increase in their
amount should be of therapeutic signiﬁcance. Such
pharmacological intervention can take place by means
of statins, which increase the amount and functional
activity of circulating progenitor endothelial cells in
experiment as well as in patients with stable disease of
coronary arteries (Vasa et al. 2001b).
It is assumed that the optimal velocity of apoptosis
of endothelial cells signiﬁcantly determinates not
only the maintenance of the integrity and normal
function of endothelium, but also that of the whole
vascular wall, because apoptosis of endothelial cells
inﬂuences also the regulation of apoptosis of smooth
muscle cells of vessels (Stoneman and Bennett
2004). An increase in apoptosis is the sign of
impaired endothelium as well as that of its turning
into pro-inﬂammatory and pro-atherogenetic pheno-
types. In progressive atherosclerotic plaques, it is a
sign of increased risk of their rupture. Stimulation of
a p o p t o s i si sc a u s e db yc l a s s i cr i s kf a c t o r so f
atherosclerosis, as, e.g. high level of blood glucose,
increased oxidation stress, oxLDL and angiotensin
II. Angioprotective factors as nitric oxide (NO) and
shear stress have a local impact, and according to
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apoptosis of endothelial cells.
One of the most important factors preserving the
integrity of endothelium is the shear stress. It is a
biomechanic force that is determined by blood
current, viscosity and the geometry of vessel. The
blood current within vessel can be of laminar or
turbulent character. Shear stress has a direct impact
on endothelium. It regulates its structures and
biologic properties by means of mechanic transfer.
Several molecules, structures and processes are
involved in turning the mechanical stimuli put into
effect by shear stress into biochemical signals resulting
in regulated transcription of various genes within
endothelial cells (Cheng et al. 2004). Their products
directly regulate the structure and biologic functions
of endothelial cells.
Laminar shear stress stimulates the expression of
anti-inﬂammatory, anti-proliferation, anti-apoptotic
and anti-oxidation genes. Proper maintenance of
normal diameter of vessels, inhibition of proliferation
of endothelial and smooth muscle cells and inhibition
of thrombotic and inﬂammatory processes are
determined by normal laminar shear stress, which in
large arteries ranges from 5 to 20dyn/cm
2 (Resnick
et al. 2003). Should it drop below 5dyn/cm
2,
atherogenesis is stimulated because such a decrease
provides mechanical and biochemical signals leading
to decreased production of NO-synthase, inhibition of
vasodilation and renewal of impaired endothelial cells.
On the other hand, the decreased value of shear stress
results in an increase in the production of reactive
oxygen intermediates, permeability for lipoproteins,
adhesion of leukocytes, apoptosis, proliferation of
smooth muscular cells and deposition of collagen. At
values over 40dyn/cm
2, the shear stress mechanically
injures the endothelium (Cunnigham and Gotlieb
2005). This means, that laminar shear stress must
have a particular signiﬁcance as to the maintenance of
the accurate adherence of individual cells to inter-
endothelial junctions and thus also to normal
structure and physiologic properties of endothelium.
In some areas of the vascular bed, e.g. in the sites of
their branching, bends or inﬂux, the shear stress
decreases, or in result of turbulent ﬂow changes
irregularly its intensity and direction resulting in
increased apoptosis of endothelial cells located herein
(Garcia-Cardena et al. 2001). Therefore, these
locations are predetermined to be the prior sites of
the origin of atherosclerotic lesions. An increased
apoptosis of endothelial cells results also in an increase
in the apoptosis of smooth muscle cells thus
decreasing their presence in atherosclerotic plaques
and increasing the risk of their rupture (Bennet 1999).
Non-laminar blood ﬂow stimulates such particular
changes in the expression of genes of endothelial cells,
in their cytoskeleton structure and correcting mech-
anisms that turn endothelial cells into inﬂammatory
and atherogenetic phenotypes. By means of inter-
cellular communication, these changes are carried
from endothelial cells over to smooth muscle cells.
Between the expression of atheroprotective and pro-
atherogenic genes within endothelial cells exists a ﬁne
balance that is regulated by the changes in shear stress.
These can result in physiological or pathological
remodelling of cells. The traditional risk factors as,
e.g. long-term hypertension, smoking, hyperchole-
sterolaemia and diabetes mellitus can disturb this
balance (Landmesser et al. 2004). Hence, the critical
function of shear stress resides in the regulation of
normal physiological atheroprotective functions of
vascular wall, as well as in the regulation of its
pathological functions with subsequent complex
changes enhancing the atherogenesis.
The decreased (insufﬁcient) or irregular shear stress
brings about an increase in apoptosis and subsequent
dysfunction of endothelium. However, an extensively
increased (more than two-fold of normal values) shear
stress has also a negative impact by means of directly
injuring the endothelium.
In result of apoptosis, the cells split into
fragments—apoptotic bodies that are wrapped in
the cytoplasmic membrane preventing the potential
cytotoxic contents to leak into the surroundings and
evoke inﬂammation. Apoptotic bodies are engulfed
especially by surrounding macrophages. Should the
velocity of this engulfment be insufﬁcient, the bodies
lose their membrane and release their content. The
latter brings about an inﬂammatory reaction and
apoptosis turns into necrosis. The engulfment of
apoptotic bodies by macrophages is inﬂuenced by
three factors: chemotactic movement of macro-
phages, the recognition and devouring of the
particle. This mechanism plays the key role in the
maintenance of tissue homeostasis of multi-cellular
organisms. It is involved also in the homeostasis of
vascular wall.
Three signals are involved in the latter: “ﬁnd-me”,
“eat-me” and “don’t-eat-me” (Lauber et al. 2004).
Should the macrophage catch the signal of ﬁrst type
emitted by apoptotic cells, it begins to move
chemotactically towards its source. In the course of
its approximation, the eat-me signals are involved
(various scavenging or lectin receptors). When the
macrophage contacts the cell in the stage of its not
being decided on apoptosis, it emits the do-not-eat-
me signal preventing the macrophages from engulf-
ment it.
Defects in regulation of local immune responses 231Recently, the ﬁnd-me type of signal has been
partially clariﬁed. It is assumed that this function is
carried out by lysophosphatidyl choline (LPC), which
is the main lipid compound of oxLDL (Lauber et al.
2003). The surface of macrophages is equipped by
LPC receptors, the fact of which implies that LPC can
function not only as a chemotactic factor emitted by
apoptotic endothelial or other cells to the attention of
macrophages and other professional phagocytes, but it
can combine also with other scavenging receptors and
enable the eat-me type of signal to be carried out. This
fact could be especially important in the pathogenesis
of atherosclerosis under the condition that LPC on
apoptotic cells is equal to LPC in oxLDL, and their
afﬁnity for corresponding receptors on the surface of
macrophages is comparable. In such cases, by means
of partial occupation of LPC receptors and scavenging
receptors on macrophages, oxLDL could slow down
its movement and engulfment of apoptotic particles
descending from endothelial and smooth muscle cells.
A delayed liquidation of remnant apoptotic cells could
be an impulse for triggering the inﬂammatory reaction
resulting in the process of atherosclerosis.
Conclusion
It is justiﬁed to assume that atherosclerosis just as
otherdiseases begins as a single pathological triggering
mechanism, which however, does not have to be equal
in each individual. The determination of this primary
event by using a simple diagnostic test would be very
beneﬁcial in prevention and effective therapy of
vascular diseases caused by atherosclerotic processes.
The experimental, epidemiologic and clinical knowl-
edge gained in recent years indicates that one of the
key players in the mechanism of atherosclerosis is the
immune system. Its part represented by vascular-
associated lymphoid tissue—VALT within the arterial
wall participates directly in the local protection from
exogenous as well as endogenous factors endangering
the vascular wall’s homeostasis. In the particular
period of ontogenetic development of an individual,
this formerly defensive and physiologic mechanism
transforms into a pathologic process resulting in an
impairing inﬂammation. Serious candidates for
triggering this pathologic change are Hsp60, CRP
and oxidized or otherwise modiﬁed LDL. Out of
them, especially the serum concentration of soluble
Hsp60, its speciﬁc antibodies and CRP could
represent a simple diagnostic test indicating that a
pathologic process is present in the vascular wall.
The principal role in the pathogenesis of athero-
sclerosis is played by shear stress originating on the
surface of endothelium due to blood ﬂow. By means of
biochemical signals, its actual values inﬂuence the
transcription of genes within endothelial cells and
thereby also the intensity and direction of their
biological responses being carried out not only in form
of protective or impairing inﬂammation, but also in
the form of structural remodelling.
During ontogenesis, the cardiovascular system over-
comesmorphologicchanges,theobjectiveofwhichisto
make this system optimal not only in securing sufﬁcient
blood, but also in guaranteeing that its movement is
within the optimal pressure range. The blood pressure
gradually increases from childhood to adulthood due to
thefactthatthetensionofvascularwallskeepschanging
and the volume of blood ejected by the heart increases
whereas the amount of cardiomyocytes stays
unchanged. These changes correspond with cellular
remodelling. Each change, including physiological
changes in blood pressure, is recorded by receptors on
the surface of endothelial cells, where from the signal is
transmitted either to the cellular nucleus where it
inﬂuences the transcription of appropriate genes or to
the cellular skeleton thus inﬂuencing the structure and
shape of cell. The changes in the transcription of genes
are reﬂected in anti- or pro-atherogenic phenotypes of
endothelium, stimulation or suppressing its inﬂamma-
tory responses. The changes in the cellular skeleton
determine the vascular remodelling which represents
theresultofadaptationtoactualpressureconditions.In
thelattercontext,atherosclerosiscouldbeconsideredas
aregulatoryremodellingfailureinsomesitesresultingin
the formation of atherosclerotic plaques. When using
this approach, the participation of immune system by
means of impairing inﬂammatory responses could be
comprehended also as an actor in remodelling
processes.
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